New wrinkle between cancer and blood coagulation: Metastasis and Cleavage of von Willebrand factor by ADAM28

Journal of the National Cancer Institute

Volumn 104, Issue 12, 2012, Pages 887-888

  Zucker, Stanley ^a,b   Cao, Jian ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM28 PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; MATRIX METALLOPROTEINASE; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

APOPTOSIS; BLOOD CLOTTING; BLOOD GROUP O; CANCER CELL; CANCER INVASION; CELL INVASION; CELL SURVIVAL; EDITORIAL; HUMAN; LUNG METASTASIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE AGGREGATION; TUMOR GROWTH;

ADAM PROTEINS; ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; TWO-HYBRID SYSTEM TECHNIQUES; VON WILLEBRAND FACTOR;

EID: 84864127594     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs251     Document Type: Editorial

References (13)

1. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol. 2012. In press.
2. Mochizuki S, Soejima K, Shimoda M, et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012; xxx (xx): xxx-xxx. doi::10.1093/jnci/djs232.
3. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007; 98 (5): 621-628. (Pubitemid 46563436)
4. Zucker S, Cao J, Chen W-T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2001; 19 (56): 6642-6650.
5. Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol. 2006; 133 : 457-467.
6. Morganti M, Capri A, Amo-Takyi B, et al. Von Willebrand's factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect. Biomed Pharmacother. 2000; 54 : 431-436.
7. Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thrombosis Res. 2007; 120 (suppl 2): 564-570.
8. Wong CW, Song C, Grimes MM, et al. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol. 2002; 161 (3): 749-753. (Pubitemid 34988360)
9. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987; 69 (6): 1691-1695. (Pubitemid 17091627)
10. Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB. ABO bood group and cancer. Eur J Cancer. 2010; 46 : 3345-3350.
11. Schellerer VS, Merkel S, Schumann SC, et al. The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res. 2011; 3 (5): 445-453.
12. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Defi cient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res. 1999; 59 : 224-2250.
13. Tritter JQ. Cancer as a chronic illness? Reconsidering categorization and exploring experience. European J Cancer Care. 2002; 11 : 161-165.